Intravenous iron supplementation — Competitive Intelligence Brief

Intravenous iron supplementation (Intravenous iron supplementation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron supplement. Area: Hematology.

marketed Iron supplement Iron (Fe2+/Fe3+) for hemoglobin and myoglobin synthesis Hematology Small molecule

Target snapshot

Intravenous iron supplementation (Intravenous iron supplementation) — University of Pecs. Intravenous iron supplementation replenishes depleted iron stores by delivering iron directly into the bloodstream for absorption and utilization in hemoglobin and myoglobin synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous iron supplementation TARGET	Intravenous iron supplementation	University of Pecs	marketed	Iron supplement	Iron (Fe2+/Fe3+) for hemoglobin and myoglobin synthesis
Iron therapy	Iron therapy	GlaxoSmithKline	marketed	Iron supplement
Iron supplement C	Iron supplement C	Tanabe Pharma Corporation	marketed	Iron supplement	Iron (Fe2+/Fe3+)
elemental iron (NovaFerrum®)	elemental iron (NovaFerrum®)	University of Texas Southwestern Medical Center	marketed	Iron supplement	Iron (Fe2+/Fe3+) — cofactor for hemoglobin and myoglobin synthesis
Ferric Pyrophosphate Liposomal	Ferric Pyrophosphate Liposomal	All India Institute of Medical Sciences	marketed	Iron supplement
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Weekly Ferrous Sulfate	Weekly Ferrous Sulfate	Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri	marketed	Iron supplement	Iron (Fe2+) for hemoglobin synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron supplement class)

1. Tanabe Pharma Corporation · 4 drugs in this class
2. Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri · 2 drugs in this class
3. Universidade Federal Fluminense · 2 drugs in this class
4. Clinica Fabia Mater · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. Hatem AbuHashim · 1 drug in this class
7. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
8. Laboratoire Innotech International · 1 drug in this class
9. Lee's Pharmaceutical Limited · 1 drug in this class
10. Milton S. Hershey Medical Center · 1 drug in this class